Bisphosphonates Induce Apoptosis of Circulating Endothelial Cells in Multiple Myeloma Patients and in Subjects with Bisphosphonate-Induced Osteonecrosis of the Jaws

被引:35
作者
Allegra, Alessandro [1 ]
Alonci, Andrea [1 ]
Penna, Giuseppa [1 ]
Granata, Angela [1 ]
Siniscalchi, Enrico Nastro [2 ]
Oteri, Giacomo [3 ]
Loddo, Saverio [4 ]
Teti, Diana [4 ]
Ciccu, Domenico [3 ]
De Ponte, Francesco Saverio [2 ]
Musolino, Caterina [1 ]
机构
[1] Univ Messina, Div Hematol, IT-98100 Messina, Italy
[2] Univ Messina, Div Oral & Maxillofacial Surg, IT-98100 Messina, Italy
[3] Univ Messina, Dept Dent, IT-98100 Messina, Italy
[4] Univ Messina, Dept Pathol & Expt Microbiol, IT-98100 Messina, Italy
关键词
Annexin V; Apoptosis; Bisphosphonates; Circulating endothelial cell; Multiple myeloma; Osteonecrosis; BREAST-CANCER PATIENTS; ANGIOGENIC FACTORS; ZOLEDRONIC-ACID; EXPERT PANEL; EXPRESSION; DENSITY; GROWTH; GENE; RATS; VEGF;
D O I
10.1159/000313787
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bisphosphonates (BPs) are the current standard of care for bone lesions in patients with multiple myeloma (MM) but they are associated with a number of side effects such as osteonecrosis of the jaw. The exact mechanisms of osteonecrosis are not elucidated, and its physiopathology is based on several hypotheses such as a decrease in bone remodeling or an inhibitory effect on angiogenesis. The aim of our study was to investigate the mechanism involved in the pathogenesis of osteonecrosis. We examined the apoptosis of circulating endothelial progenitor cells in MM subjects before and after BP treatment and in osteonecrosis patients using a flow-cytometric analysis. Our data showed an increase in endothelial cell apoptosis in MM patients after BP administration and in osteonecrosis subjects. Our study seems in agreement with the hypothesis that BPs can inhibit angiogenesis interfering with endothelial cell proliferation and survival, leading to loss of blood vessels and avascular necrosis. Copyright (c) 2010 S. Karger AG, Basel
引用
收藏
页码:79 / 85
页数:7
相关论文
共 40 条
[1]   Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells [J].
Allegra, A. ;
Oteri, G. ;
Nastro, E. ;
Alonci, A. ;
Bellomo, G. ;
Del Fabro, V. ;
Quartarone, E. ;
Alati, C. ;
De Ponte, F. S. ;
Cicciu, D. ;
Musolino, C. .
HEMATOLOGICAL ONCOLOGY, 2007, 25 (04) :164-169
[2]   The Pathogenesis of Bisphosphonate-Related Osteonecrosis of the Jaw: So Many Hypotheses, So Few Data [J].
Allen, Matthew R. ;
Burr, David B. .
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2009, 67 (05) :61-70
[3]   Patients with bisphosphonate-associated osteonecrosis of the jaw have unmodified levels of soluble vascular endlothelial growth factor receptor 1 [J].
Alonci, Andrea ;
Allegra, Alessandro ;
Bellomo, Giacomo ;
Quartarone, Eugenia ;
Oteri, Giacomo ;
Nastro, Enrico ;
Cicciu, Domenico ;
De Ponte, Francesco Saverio ;
Musolino, Caterina .
LEUKEMIA & LYMPHOMA, 2007, 48 (09) :1852-1854
[4]  
AONS K, 2009, ORAL SURG ORAL MED O, V107, P1
[5]   Oral Bisphosphonates as a Cause of Bisphosphonate-Related Osteonecrosis of the Jaws: Clinical Findings, Assessment of Risks, and Preventive Strategies [J].
Assael, Leon A. .
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2009, 67 (05) :35-43
[6]   Guideline for the flow cytometric enumeration of CD34+ haematopoietic stem cells [J].
Barnett, D ;
Janossy, G ;
Lubenko, A ;
Matutes, E ;
Newland, A ;
Reilly, JT .
CLINICAL AND LABORATORY HAEMATOLOGY, 1999, 21 (05) :301-308
[7]   Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: Implications for use as a surrogate marker of antiangiogenic activity [J].
Beaudry, P ;
Force, J ;
Naumov, GN ;
Wang, A ;
Baker, CH ;
Ryan, A ;
Soker, S ;
Johnson, BE ;
Folkman, J ;
Heymach, JV .
CLINICAL CANCER RESEARCH, 2005, 11 (09) :3514-3522
[8]   Apoptotic vascular endothelial cells become procoagulant [J].
Bombeli, T ;
Karsan, A ;
Tait, JF ;
Harlan, JM .
BLOOD, 1997, 89 (07) :2429-2442
[9]   Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells [J].
Carneiro, Angela ;
Falcao, Manuel ;
Pirraco, Ana ;
Milheiro-Oliveira, Paula ;
Falcao-Reis, Fernando ;
Soares, Raquel .
EXPERIMENTAL EYE RESEARCH, 2009, 88 (03) :522-527
[10]   Effects of Risedronate on Alveolar Bone Loss and Angiogenesis: A Stereologic Study in Rats [J].
Cetinkaya, Burcu Ozkan ;
Keles, Gonca Cayir ;
Ayas, Bulent ;
Gurgor, Pinar .
JOURNAL OF PERIODONTOLOGY, 2008, 79 (10) :1950-1961